Abstract：Objective: To investigate the risk factors affecting tumor recurrence after pheochromocytoma （PCC） surgery, to predict postoperative recurrence in patients with PCC, and to provide assistance in reducing PCC recurrence. Methods: A retrospective analysis of 310 patients who were hospitalized and underwent tumor resection for PCC at our center from 2012 January to 2020 June was conducted to compare the clinical and postoperative outcomes of patients who underwent surgical treatment,multivariate logistic regression analysis of risk factors for tumor recurrence after surgery. Results: Compared with nonrecurrence group,young age, comorbid hypertension, history of previous pheochromocytoma recurrence, Ki-67 level, and high bilateral probability of neoplasia were significant in the rucurrence group （P<0.05）.Multivariate logistic regression analysis showed age [OR=5.765, 95% CI： 0.926-0.992; P=0.016], comorbid hypertension [OR=5.767, 95% CI： 1.306-13.995; P=0.016], history of previous recurrence of pheochromocytoma [OR=18.655, 95% CI： 4.455-53.320; P<0.001], admission diastolic pressure [OR=4.400, 95% CI： 0.286-4.710; P=0.036], bilateral tumors [OR=0.044, 95% CI： 1.030-1.079; P=0.834] were risk factors of postoperative recurrence. Conclusion: Age, comorbid hypertension, history of recurrent pheochromocytoma, and diastolic blood pressure were independent factors for recurrence of PCC tumors.
[1] Young WF. Adrenal causes of hypertension: pheochromocytoma and primary aldosteronism[J]. Rev Endocr Metab Disord, 2007, 8(4): 309-320. [2] 王艳丽, 滕晓东.嗜铬细胞瘤/副神经节瘤的TNM分期进展[J]. 中华病理学杂志, 2019,48(6): 501-504. [3] Farrugia FA, Charalampopoulos A. Pheochromocytoma[J]. EndocrRegul, 2019, 53(3): 191-212. [4] Cui YY,Ma XS, Gao YJ, et al. Local-regional recurrence of pheochromocytoma/ paraganglioma: characteristics, risk factors and outcomes[J]. Front Endocrinol (Lausanne), 2021,12: 762548. [5] Andrici J, Gill AJ, Hornick JL. Next generation immunohistochemistry: Emerging substitutes to genetic testing?[J]. Semin Diagn Pathol, 2018. 35(3): 161-169. [6] Fliedner SMJ, Brabant G, Lehnert H. Pheochromocytoma and paraganglioma: genotype versus anatomic location as determinants of tumor phenotype[J]. Cell Tissue Res, 2018,372(2): 347-365. [7] Giubellino A, Lara K, Martucci V, et al. Urinary bladder paragangliomas: how immunohistochemistry can assist to identify patients with SDHB germline and somatic mutations[J]. Am J Surg Pathol, 2015, 39(11): 1488-1492. [8] Pasini B, Stratakis CA. SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes[J]. J Intern Med, 2009, 266(1): 19-42. [9] Gill AJ. Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia[J]. Pathology, 2012, 44(4): 285-292. [10] Waguespack SG, Rich T, Grubbs E, et al. A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma[J]. J Clin Endocrinol Metab, 2010 ,95(5): 2023-2037. [11] Pamporaki C, Hamplova B, Peitzsch M, et al. Characteristics of pediatric vs adult pheochromocytomas and paragangliomas[J]. J Clin Endocrinol Metab, 2017, 102(4): 1122-1132. [12] Young WF, Maddox DE. Spells: in search of a cause[J]. Mayo Clin Proc, 1995 , 70(8): 757-765. [13] Pappachan JM, Tun NN, Arunagirinathan G, et al. Pheochromocytomas and hypertension[J]. Curr Hypertens Rep, 2018, 20(1): 3. [14] Turchini J, Cheung VKY, Tischler AS, et al. Pathology and genetics of phaeochromocytoma and paraganglioma[J]. Histopathology, 2018, 72(1);97-105. [15] Lenders JWM, Pacak K, WaltherM CM, et al. Biochemical diagnosis of pheochromocytoma: which test is best?[J]. JAMA, 2002,287(11): 1427-1434. [16] Walther MM, Reiter R, Keiser HR, et al. Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma[J]. JUrol, 1999,162(3 Pt 1): 659-664. [17] DeLellis RA. Does the evaluation of proliferative activity predict malignancy of prognosis in endocrine tumors?[J].Hum Pathol, 1995, 26(2): 131-134. [18] Donhuijsen K. Mitosis counts: reproducibility and significance in grading of malignancy[J]. Hum Pathol, 1986, 17(11): 1122-1125. [19] Sessa L, Nomine-Criqui C , Germainet A, et al. Robotic transperitoneal left adrenalectomy for a 10cm pheochromocytoma (with video)[J]. J Visc Surg, 2016, 153(4): 307-308. [20] Sessa L, Nomine C, Germainet A, et al. Right robotic adrenalectomy for a 8 cm pheochromocytoma (with video)[J]. J Visc Surg, 2015, 152(5): 334-335. [21] Galati SJ, Said M, Gospin R, et al. The mount sinai clinical pathway for the management of pheochromocytoma[J]. Endocr Pract, 2015 ,21(4): 368-382. [22] Heger P, Probst P, HüttneretF J, et al. Evaluation of open and minimally invasive adrenalectomy: asystematic review and network meta-analysis[J]. World JSurg, 2017, 41(11): 2746-2757. [23] Brunaud L, Nguyen-Thi PL, Mirallie E, et al. Predictive factors for postoperative morbidity after laparoscopic adrenalectomy for pheochromocytoma: a multicenter retrospective analysis in 225 patients[J]. Sur Endosc, 2016, 30(3): 1051-1059. [24] Lenders JWM, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2014,99(6): 1915-1942. [25] Press D, Akyuz M, Dural C, et al. Predictors of recurrence in pheochromocytoma[J]. Surgery, 2014, 156(6): 1523-1528.
